Table 1.
Demographic and clinical characteristics of cohorts included in meta-analysis.
| Authors | Country (Year) |
Nr. Patients SA/Placebo |
Study design | Intervention duration (weeks) | Mean age (years) |
Female gender (%) | Mean eGFR (ml/min) |
Study drug | Liver volume scan | Presence of ADPLD | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Van Keimpema et al | Netherlands (2009) | 27/27 | Randomized, double-blind, placebo-controlled trial | 24 | 49.6 | 87 |
69 (MDRD) |
Lanreotide 120 mg subcutaneously every 28 days | CT | Yes | TLV, HRQL |
| Caroli et al | Italy (2010) | 12/12 | Post-hoc analysis of a randomized, crossover, placebo-controlled trial | 24 | 44.5 | 25 |
57 (iohexol clearance) |
Octreotide LAR 40 mg intramuscularly every 28 days | CT | No | TLV |
| Hogan et al | US (2010) | 28/14 | Randomized, double-blind, placebo-controlled trial | 52 | 49.7 | 86 |
70 (iothalamate clearance) |
Octreotide LAR 40 mg intramuscularly every 28 days | MRI/CT | Yes | TLV, HRQL |
| Pisani et al | Italy (2016) | 14/13 | Post-hoc analysis of a randomized controlled trial | 156 | 33.4 | 63 |
92 (iohexol clearance) |
Octreotide LAR 40 mg intramuscularly every 28 days | MRI | No | TLV |
| Van Aerts et al |
Netherlands (2019) |
83/74 | Secondary analysis of a randomized controlled trial | 120 | 48.2 | 53 |
51 (MDRD) |
Lanreotide 120 mg subcutaneously every 28 days | MRI | No | TLV |
| Hogan et al | US (2020) | 29/12 | Randomized, double-blind, placebo-controlled trial | 52 | 50.8 | 93 |
72 (CKD-EPI) |
Pasireotide LAR 60 mg intramuscularly every 28 days | MRI | Yes | TLV, HRQL |
SA somatostatin analogue, LAR long-acting release, CT computed tomography, MRI magnetic resonance imaging, TLV total liver volume, TKV total kidney volume, eGFR estimated glomerular filtration rate, HRQL health-related quality of life, ADPLD autosomal dominant polycystic liver disease.